Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbbVie

187.15
-8.9200-4.55%
Pre-market: 187.500.3500+0.19%09:28 EDT
Volume:9.39M
Turnover:1.77B
Market Cap:331.06B
PE:79.98
High:195.82
Open:195.50
Low:185.74
Close:196.07
Loading ...

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

PR Newswire
·
08 Apr

AbbVie (NYSE:ABBV) Showcases Cancer Treatment Advancements at AACR Annual Meeting

Simply Wall St.
·
08 Apr

Tariffs Pose $46 Billion Risk to Pharmaceutical Industry -- Analysis

Dow Jones
·
05 Apr

Shares of Some U.S. Drugmakers Down After Trump Says Pharmaceutical Sector Is 'Under Review' for Tariffs

THOMSON REUTERS
·
04 Apr

BUZZ-US drugmakers fall after Trump's new tariff warnings

Reuters
·
04 Apr

AbbVie (ABBV) Stock Moves -1.73%: What You Should Know

Zacks
·
04 Apr

AbbVie Issues Q1 Adjusted Earnings Outlook, Cuts Full-Year Guidance

MT Newswires Live
·
04 Apr

AbbVie cuts 2025 profit forecast on acquisition expenses

Reuters
·
04 Apr

BRIEF-Abbvie Inc - Q1 2025 Earnings Include $248 Million Ipr&D And Milestones Expense - SEC Filing

Reuters
·
04 Apr

Abbvie Inc - Q1 2025 Adjusted EPS Guidance $2.34 - $2.38 - SEC Filing

THOMSON REUTERS
·
04 Apr

Abbvie Inc - Q1 2025 Earnings Include $248 Million Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS
·
04 Apr

Abbvie Inc Q1 Shr View $2.51 -- Lseg Ibes Data

THOMSON REUTERS
·
04 Apr

Potatoes, discount chains and drugmakers offer havens in stock-market bloodbath

Dow Jones
·
04 Apr

BUZZ-US drugmakers rise on reprieve from Trump tariffs

Reuters
·
03 Apr

Shares of US Drugmakers Rise After Tariff Exemption

THOMSON REUTERS
·
03 Apr

Shares of Abbvie up 2.5%, Johnson & Johnson up 2.5%, Merck up 1.9%, Amgen up 2.2%

THOMSON REUTERS
·
03 Apr

LIVE MARKETS-Tariff risks, is pharma out of the woods?

Reuters
·
03 Apr

Bernstein Keeps Their Hold Rating on AbbVie (ABBV)

TIPRANKS
·
03 Apr

Top AbbVie Executive Cashes in Millions from Stock Sale

TIPRANKS
·
03 Apr

AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?

Zacks
·
02 Apr